Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
Healthcare
$0.78 +0.50%
+$0.02 today
- Market cap
- $94.67M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
52W Low $1.96High $6.16
Volume 1.84M
Average 1.44M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$82.48M
FY 2025 · Annual
Investing Cash Flow
$41.23M
FY 2025 · Annual
Financing Cash Flow
$10.30M
FY 2025 · Annual
-96.4% YoYCash Flow Statement
USD
Metric | FY 2021 Jun 2022 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.27M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Depreciation & Amortization | 248K | 344K | 946K | 2.31M | 3.25M |
| Deferred Income Tax | 0 | (1.68M) | (2.65M) | (2.1M) | (793K) |
| Stock-Based Compensation | 1.09M | 1.34M | 3.74M | 5.39M | 8.97M |
| Change in Working Capital | (1.85M) | 338K | 2.3M | 31.81M | 1.68M |
| Accounts Receivables | 405K | 490K | (426K) | 1.05M | (32K) |
| Inventory | (2.67M) | (152K) | 359K | 11K | 0 |
| Accounts Payables | 236K | 0 | 1.58M | 1.89M | 147K |
| Other Working Capital | 182K | (28K) | 779K | 29.74M | 1.57M |
| Other Non-Cash Items | 77K | 472K | 5.27M | 55.39M | 7.53M |
| Operating Cash Flow | (7.71M) | (12.17M) | (36.91M) | (18.29M) | (82.48M) |
| Capital Expenditures | (266K) | (302K) | (1.07M) | (54.41M) | (12.75M) |
| Acquisitions (Net) | 0 | 0 | 2.7M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (243.51M) | (119.84M) |
| Sales of Investments | 0 | 0 | 22.76M | 0 | 173.95M |
| Other Investing Activities | (18K) | (57.38M) | (18K) | 78.99M | (135K) |
| Investing Cash Flow | (284K) | (57.68M) | 24.37M | (218.93M) | 41.23M |
| Debt Repayment | — | — | (68K) | (48K) | (52K) |
| Common Stock Issued | 56K | 0 | 364K | 275.81M | 10.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 56K | 489K | 289.39M | 0 |
| Financing Cash Flow | 56K | 56K | 785K | 289.39M | 10.31M |
| Effect of Forex Changes | 0 | 61.86M | 0 | 0 | 0 |
| Net Change in Cash | (7.94M) | 182K | (46.65M) | 52.16M | (30.95M) |
| Free Cash Flow | (7.98M) | (12.47M) | (37.99M) | (72.71M) | (95.23M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$103.1M
+ D&A$3.3M
+ Stock-Based Comp$9.0M
- Deferred Tax-$793.0K
+ Working Capital$1.7M
+ Other Non-Cash$7.5M
= Operating Cash Flow-$82.5M
- Capex-$12.7M
= Free Cash Flow-$95.2M
Analysis
FY2025 free cash flow is -$95.2M. FCF conversion is 92.4% of net income. Operating cash flow was -$82.5M, with capex of -$12.7M. The largest bridge item is Capex at -$12.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 |
Does CATX generate free cash flow?
Perspective Therapeutics, Inc. (CATX) generated -$95.23M of free cash flow in fiscal 2025.
How much operating cash flow does CATX produce?
Operating cash flow was -$82.48M, before capital expenditures of $12.75M.
Continue the stock analysis
Jump to another research area for this company.